Clinical trial
BAY 59-8862 in Treating Patients With Advanced Kidney Cancer
NCT00039169 · Theradex, Industry · Unknown status
Key facts
| NCT number | NCT00039169 |
|---|---|
| Title | BAY 59-8862 in Treating Patients With Advanced Kidney Cancer |
| Official title | An Uncontrolled Phase II Multi-Center Trial Evaluating Anti-Tumor Efficacy and Safety of BAY 59-8862 in Patients With Advanced Renal Cell Cancer |
| Lead sponsor | Theradex, Industry |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Kidney Cancer |
| Intervention type | Drug |
| Interventions | ortataxel |
| Start date | Dec 1, 2001 |
| First posted | Jul 8, 2003 |
| Last update posted | Jul 24, 2008 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: